肿瘤细胞治疗研究
英文原题：T-Cell Engagers Targeting BCMA, GPRC5D, or FcRH5 in Relapsed/Refractory Multiple Myeloma: The Landscape Beyond CAR-T Cell Therapy-A Systematic Review and Network Meta-Analysis.
我们手动检索了七个数据库，并确定了44项研究进行定量分析。
复发/难治性多发性骨髓瘤以频繁的三类难治和生存期差为特征，而靶向 BCMA、GPRC5D 或 FcRH5 的双特异性抗体即使在重度经治和 BCMA 治疗后疾病中仍显示出有意义的活性。本 meta 分析利用直接和间接证据评估并比较这些药物在 RRMM 中的疗效和安全性。我们手动检索了 7 个数据库，并确定了 44 项研究进行定量分析。使用 R 4.1.1 软件创建森林图。与标准治疗（SOC）相比，Talquetamab、Teclistamab、Elranatamab 和 Linvoseltamab 的客观缓解率（ORR）优势比更高（5.73、4.86、3.84 和 2.63）。PFS 在 Teclistamab（HR 0.50，95% CI 0.36-0.55）、Talquetamab（0.50，0.36-0.55）、Elranatamab（0.45，0.36-0.55）和 Linvoseltamab（0.23，0.17-0.31）中改善。相对于 SOC，Linvoseltamab 和 Elranatamab 显示数值上更长的 OS（分别为 HR 0.41，0.24-0.70 和 HR 0.58，0.43-0.78），但 Teclistamab（HR 1.82，1.37-2.42）和 Talquetamab（HR 1.75，1.20-2.57）显示数值上更短的 OS。在汇总的单臂数据中，Talquetamab 的 ORR 最高（72%），CRS 发生率也最高（68%）；Teclistamab 显示 ORR 为 61%，CRS 发生率为 61%，Linvoseltamab 显示 ORR 为 60%，CRS 发生率为 51%。Cevostamab 和 Elranatamab 的 ORR 分别为 49% 和 56%，CRS 发生率分别为 61% 和 52%。在 RRMM 中，与 SOC 相比，所有双特异性抗体均显示出更优的 ORR 以及改善的 PFS。在调整后的跨试验比较限制范围内，相对于 SOC，Linvoseltamab 和 Elranatamab 显示数值上更长的 OS，而 Talquetamab 和 Teclistamab 相对于 SOC 显示数值上更短的 OS。
Relapsed/refractory multiple myeloma is marked by frequent triple-class refractoriness and poor survival, whereas bispecific antibodies targeting BCMA , GPRC5D , or FcRH5 show meaningful activity even in heavily pretreated and post-BCMA disease. This meta-analysis evaluates and compares the efficacy and safety of these agents in RRMM using direct and indirect evidence. We manually searched seven databases and identified 44 studies for quantitative analysis. Forest plots were created using R 4.1.1 software. Compared to Standard of care (SOC), the odds of Objective response rate (ORR) were higher with Talquetamab, Teclistamab, Elranatamab, and Linvoseltamab (5.73, 4.86, 3.84, and 2.63). PFS improved with Teclistamab (HR 0.50, 95% CI 0.36-0.55), Talquetamab (0.50, 0.36-0.55), Elranatamab (0.45, 0.36-0.55), and Linvoseltamab (0.23, 0.17-0.31). Linvoseltamab and Elranatamab showed numerically longer OS relative to SOC (HR 0.41, 0.24-0.70 and HR 0.58, 0.43-0.78, respectively), but numerically shorter OS with Teclistamab (HR 1.82, 1.37-2.42) and Talquetamab (HR 1.75, 1.20-2.57). In pooled single-arm data, Talquetamab had the highest ORR (72%) and CRS rate (68%); Teclistamab showed an ORR of 61% with a CRS rate of 61% and Linvoseltamab showed an ORR of 60% with a CRS rate of 51%. Cevostamab and Elranatamab had ORRs of 49% and 56% with CRS rates of 61% and 52%, respectively. In RRMM, all bispecific antibodies showed superior ORR along with improved PFS compared to SOC. Linvoseltamab and Elranatamab showed numerically longer OS relative to SOC, whereas Talquetamab and Teclistamab showed numerically shorter OS versus SOC, within the constraints of adjusted cross-trial comparisons.
MEMBER ACCOUNT
登录成功会直接打开下一页。
